Chemkart India Posts Strong Q1 FY27 Revenue, Pivots from Supplier to Solutions Partner

Chemkart India Posts Strong Q1 FY27 Revenue, Pivots from Supplier to Solutions Partner​

Chemkart India Ltd has reported robust performance for the first quarter of fiscal year 2027 (Apr-Jun), achieving strong revenue growth while simultaneously reinforcing its transition into a solutions-driven partner in the nutraceutical and specialty ingredients industry. The company highlighted strategic investments in research and development (R&D) and significant progress toward commissioning its new manufacturing facility.

The financial snapshot for April to June FY27 showed revenue from operations standing at INR 9,960.22 lakhs. This performance represents achieving nearly half of the previous financial year's full-year revenue in just three months, demonstrating rapid and disciplined growth momentum.

Strategic Evolution and R&D Focus​

The company is undergoing a strategic shift, evolving beyond merely supplying products to becoming a complete solutions provider for manufacturers. Chemkart now assists customers by offering ingredient selection, application support, formulation guidance, and reliable quality-assured supply. This transition aims to deepen customer relationships and improve margin quality.

Investment in R&D remains a core focus, with 20 projects currently in the pipeline for April–June FY27. This commitment extends to the subsidiary, Vinstar Biotech Private Limited, which received trial orders from multiple customers for value-added ingredients developed in-house. This marks the Group's first steps as a developer of proprietary formulations rather than just an ingredient supplier.

Operational and Capacity Building​

Chemkart is concurrently focusing on building essential operational capabilities, including strengthening quality and compliance frameworks, improving sourcing efficiency, and shortening turnaround timelines.

The manufacturing initiative under Easy Raw Materials Private Limited (EZRM) has progressed according to schedule. Key milestones reached during the period include:

• Plinth-level construction of Unit-1 completion.
• Receipt of the Electricity Sanction Letter, securing power infrastructure for the facility.
• Finalization of packaging machinery, which is scheduled for delivery within 30–35 days of purchase order release.

The company has also strengthened its global footprint and expanded its customer base, adding 15 key customers in the April-June FY27 period. Strategic expansions are planned across functional and value-added ingredient categories, including proteins, functional fibres, and salt reduction solutions.

Market Trends and Industry Outlook​

The broader nutraceutical industry is continuing its strong upward trajectory, driven by preventive healthcare adoption and rising lifestyle-related health concerns globally. The demand landscape is shifting from volume towards value, with a particular focus on targeted ingredients such as gut health, proteins, and adaptogens.

Market projections indicate that the global nutraceutical market is expected to cross USD 550+ billion in 2026. In India, the market was estimated at $37–$38 billion in 2026 and is projected to reach $55–$57 billion by 2030, representing a 10.5% CAGR (according to Grand View Research and Precedence Research).

The industry consensus suggests a structural shift from volume-driven growth toward science-backed, value-driven, and supply-stable ecosystems, favoring integrated ingredient partners with deep sourcing knowledge and manufacturing reliability.

Stock Price Movement​

As of 14:25, Chemkart India Ltd is edging higher, currently trading at ₹203.00 and reflecting a solid 3.39% gain. The shares moved through a wide intraday range today, with the stock touching a low of ₹186.65 before peaking near ₹206.15.